secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001437749-25-031162
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Talphera appoints Joseph Todisco (CorMedix CEO) to board; grants RSUs and options
--------------------------------------------------------------------------------

- Joseph Todisco appointed Class III director and compensation committee member effective Oct 14, 2025.
- Todisco is CEO of CorMedix; appointment per Sept 2025 securities purchase agreement.
- Granted 6,397 RSUs and options for 38,381 shares at $1.11, vesting in three equal annual installments.
- CorMedix retains right to designate one board member while holding >=25% of shares from private placement.
- CorMedix gets 60-day exclusive right to negotiate acquisition of Talphera after Niyad NEPHRO CRRT results, until Dec 31, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925031162/0001437749-25-031162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925031162/acrx20251015_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer